Identification of CDKN3 as a Key Gene that Regulates Neuroblastoma Cell Differentiation

Alexandra Vernaza1, Daniela F Cardus1, Jadyn L Smith1

  • 1Department of Chemistry and Biochemistry, Texas State University, San Marcos, Texas.

Journal of Cancer
|February 15, 2024
PubMed

Insights

Cyclin dependent kinase inhibitor 3 (CDKN3) knockdown induces neuroblastoma cell differentiation and neurite outgrowth. High CDKN3 levels correlate with poor patient survival, suggesting its role in neuroblastoma progression.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Neuroblastoma is a pediatric cancer with complex cell cycle regulation.
  • Identifying regulators of neuroblastoma differentiation is crucial for therapeutic strategies.

Purpose of the Study:

  • To identify cell cycle regulators controlling neuroblastoma differentiation.
  • To investigate the role of Cyclin dependent kinase inhibitor 3 (CDKN3) in neuroblastoma cell differentiation and progression.

Main Methods:

  • High-content screening (HCS) using siRNA library in BE(2)-C neuroblastoma cells.
  • Analysis of cell differentiation markers (neurite outgrowth, NSE, βIII-tubulin, GAP43) and proliferation markers (Ki67, PCNA).
  • Correlation analysis with public neuroblastoma patient datasets and investigation of CDKN3 regulatory mechanisms (N-Myc, miR-506-3p, retinoic acid).

Main Results:

  • CDKN3 knockdown significantly induced neuroblastoma cell differentiation and neurite outgrowth.
  • CDKN3 knockdown reduced proliferation markers and colony formation.
  • High tumor CDKN3 mRNA levels correlated with poor patient survival.
  • N-Myc transcriptionally promoted CDKN3 expression, while miR-506-3p and retinoic acid down-regulated it.
  • CDKN3 interacts with CDC6 and CDK4 in a differentiation-regulating network.

Conclusions:

  • CDKN3 plays a critical role in regulating neuroblastoma cell differentiation.
  • N-Myc-mediated transcriptional regulation of CDKN3 is a key mechanism in neuroblastoma.
  • Overexpression of CDKN3 may contribute to neuroblastoma progression and warrants further investigation as a therapeutic target.